Platelet recovery rate during plasma exchange predicts early and late responses in patients with thrombotic thrombocytopenic purpura (CME)

被引:7
作者
Liu, Chang
Kallogjeri, Dorina
Dynis, Marian
Grossman, Brenda J.
机构
[1] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Otolaryngol, St Louis, MO 63110 USA
[3] Barnes Jewish Hosp, Apheresis Ctr, St Louis, MO 63110 USA
关键词
HEMOLYTIC-UREMIC SYNDROME; VON-WILLEBRAND-FACTOR; FACTOR-CLEAVING PROTEASE; TTP-HUS REGISTRY; ADAMTS13; MULTICENTER; EXPERIENCE; ANTIBODIES; OUTCOMES;
D O I
10.1111/j.1537-2995.2012.03857.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Therapeutic plasma exchange (TPE) is the first-line therapy for patients with thrombotic thrombocytopenic purpura (TTP). However, therapeutic response to TPE and late prognosis vary among different patients, and predictors of these outcomes may help customize treatments to individual patients. STUDY DESIGN AND METHODS: We retrospectively examined the platelet (PLT) recovery rate (PRR) in 64 consecutive patients with initial episode of TTP who received TPE in our institution between 2003 and 2010. PRRs were calculated by linear regression of the PLT counts at the start and during the first few days of TPE treatment. Its relationship with remission in response to TPE, exacerbation and relapse, and survival was analyzed by univariate and multivariate analysis. RESULTS: With multivariate analysis, which included ADAMTS13 activities, patients with a PRR by Day 3 (PRR3) of 5x109/L per 24 hours or above were 18 times more likely to achieve remission in response to TPE than those with a lower PRR3 (p<0.001). In addition, short-term exacerbations and relapses beyond 1 month of remission occurred almost exclusively in patients with a PRR3 of 5x109/L per 24 hours or above. Survival was significantly better in these patients than in patients with PRR3 below the cutoff (p<0.001), and the hazard ratio adjusted for ADAMTS13 and age was 23.2 (p<0.005). CONCLUSION: PRR3 with a cutoff of 5x109/L per 24 hours provides a practical approach to risk stratify TTP patients receiving TPE early in their treatment and may guide the decision making both at initial encounters and during the long-term follow-up.
引用
收藏
页码:1096 / 1107
页数:12
相关论文
共 27 条
  • [1] Therapeutic plasma exchange for the treatment of thrombotic thrombocytopenic purpura: A retrospective multicenter study
    Altuntas, Fevzi
    Aydogdu, Ismet
    Kabukcu, Sibel
    Kocyigit, Ismail
    Cikim, Kerim
    Sari, Ismail
    Erkut, M. Ali
    Eser, Bulent
    Ozturk, Ahmet
    Kaya, Emin
    Cetin, Mustafa
    Keskin, Ali
    Unal, Ali
    [J]. TRANSFUSION AND APHERESIS SCIENCE, 2007, 36 (01) : 57 - 67
  • [2] THROMBOTIC THROMBOCYTOPENIC PURPURA - REPORT OF 16 CASES AND REVIEW OF LITERATURE
    AMOROSI, EL
    ULTMANN, JE
    [J]. MEDICINE, 1966, 45 (02) : 139 - +
  • [3] Bandarenko N, 1998, J CLIN APHERESIS, V13, P133, DOI 10.1002/(SICI)1098-1101(1998)13:3<133::AID-JCA7>3.0.CO
  • [4] 2-Z
  • [5] A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura
    Brunskill, S. J.
    Tusold, A.
    Benjamin, S.
    Stanworth, S. J.
    Murphy, M. F.
    [J]. TRANSFUSION MEDICINE, 2007, 17 (01) : 17 - 35
  • [6] Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura
    Cataland, Spero R.
    Yang, Shang-bin
    Witkoff, Leslie
    Kraut, Eric H.
    Lin, Shili
    George, James N.
    Wu, Haifeng M.
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 83 (06) : 559 - 564
  • [7] Thrombotic Microangiopathy: Current Knowledge and Outcomes With Plasma Exchange
    Clark, William F.
    [J]. SEMINARS IN DIALYSIS, 2012, 25 (02) : 214 - 219
  • [8] ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13
    Davis, Amanda K.
    Makar, Robert S.
    Stowell, Christopher P.
    Kuter, David J.
    Dzik, Walter H.
    [J]. TRANSFUSION, 2009, 49 (02) : 206 - 213
  • [9] Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura?
    Fakhouri, Fadi
    Fremeaux-Bacchi, Veronique
    [J]. NATURE CLINICAL PRACTICE NEPHROLOGY, 2007, 3 (12): : 679 - 687
  • [10] Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus)
    Feys, Hendrik B.
    Roodt, Jan
    Vandeputte, Nele
    Pareyn, Inge
    Lamprecht, Seb
    van Rensburg, Walter J.
    Anderson, Patricia J.
    Budde, Ulrich
    Louw, Vernon J.
    Badenhorst, Philip N.
    Deckmyn, Hans
    Vanhoorelbeke, Karen
    [J]. BLOOD, 2010, 116 (12) : 2005 - 2010